A retrospective study assessing the safety including the incidence of infections and malignancies in patients treated with Ocrelizumab for relapsing-remitting, secondary-progressive and primary progressive multiple sclerosis
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 15 Dec 2021 New trial record